Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(05): 539-548
DOI: 10.1055/a-1464-1221
GebFra Science
Review/Übersicht

Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers

Article in several languages: English | deutsch
Nina Ditsch
1   Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
,
Elmar Stickeler
2   Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen, Germany
,
Annika Behrens
3   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Erik Belleville
4   ClinSol GmbH & Co. KG, Würzburg, Germany
,
Peter A. Fasching
3   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Tanja N. Fehm
5   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
,
Andreas D. Hartkopf
6   Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
,
Christian Jackisch
7   Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Offenbach, Germany
,
Wolfgang Janni
8   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Cornelia Kolberg-Liedtke
9   Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany
,
Hans-Christian Kolberg
10   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Diana Lüftner
11   Charité University Hospital, Department of Hematology, Oncology and Tumour Immunology, University Medicine Berlin, Berlin, Germany
,
Michael P. Lux
12   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany
,
Volkmar Müller
13   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Andreas Schneeweiss
14   National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
,
Florian Schütz
15   Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany
,
Carla E. Schulmeyer
3   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Hans Tesch
16   Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany
,
Christoph Thomssen
17   Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
,
Christoph Uleer
18   Praxisgemeinschaft Frauenärzte am Bahnhofsplatz, Hildesheim, Germany
,
Michael Untch
19   Clinic for Gynecology and Obstetrics, Breast Cancer Center, Genecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany
,
Manfred Welslau
20   Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Achim Wöckel
21   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Lena A. Wurmthaler
3   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Rachel Würstlein
22   Breast Center, Department of Gynecology and Obstetrics and CCC Munich Ludwig Maximilians University, LMU University Hospital, Munich, Germany
,
Marc Thill
23   Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany
,
Bahriye Aktas
24   Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Leipzig, Leipzig, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

This review summarises and discusses significant aspects of recently published studies on patient treatment in advanced breast cancer and on biomarkers in breast cancer. In recent years, a large number of drugs for all molecular subtypes have been developed up to phase III trials. With regard to immune checkpoint inhibitors in metastasised breast cancer, the recent discussion has centred on the best candidate for combined chemotherapy. The oral taxanes could become a new type of oral chemotherapies. There is a growing body of data on biomarkers for the use of CDK4/6 inhibitors, which could also signify further development for other molecular subtypes. New substances have been developed for metastatic HER2+ breast cancer that still result in good remission even after massive prior treatment and/or cerebral metastasis. Similarly, knowledge is growing about targeted therapies with antibody-drug conjugates (ADC) against Trop-2, which could bolster our therapeutic armoury in triple-negative breast cancer (TNBC). In addition, the clinical focus is on understanding how to maintain fertility after breast cancer treatment. Here, pooled analyses provide new insights.

Key words

advanced breast cancer - biomarkers - therapy - prognosis


Publication History

Received: 17 March 2021

Accepted after revision: 23 March 2021

Article published online:
03 May 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Ditsch N, Untch M, Thill M. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel) 2019; 14: 224-245
    CrossrefPubMedGoogle Scholar
  • 2 Ditsch N, Untch M, Kolberg-Liedtke C. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. Breast Care (Basel) 2020; 15: 294-309
    CrossrefPubMedGoogle Scholar
  • 3 Tesch H, Müller V, Wöckel A. et al. Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80: 1115-1122
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Schneeweiss A, Hartkopf AD, Müller V. et al. Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Frauenheilkd 2020; 80: 277-287
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Lüftner D, Schneeweiss A, Hartkopf AD. et al. Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Frauenheilkd 2020; 80: 391-398
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Huober J, Schneeweiss A, Hartkopf AD. et al. Update Breast Cancer 2020 Part 3 – Early Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80: 1105-1114
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Miles DW, Gligorov J, André F. et al. Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Ann Oncol 2020; 31 (Suppl. 04) S1142-S1215 doi:10.1016/annonc/annonc325
    CrossrefPubMedGoogle Scholar
  • 8 Schmid P, Adams S, Rugo HS. et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2019; 37 (15 Suppl.): 1003-1003
    PubMedGoogle Scholar
  • 9 Schmid P, Adams S, Rugo HS. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379: 2108-2121
    CrossrefPubMedGoogle Scholar
  • 10 Cortes J, Cescon DW, Rugo HS. et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J Clin Oncol 2020; 38 (15 Suppl.): 1000
    CrossrefPubMedGoogle Scholar
  • 11 Rugo HS, Schmid P, Cescon DW. et al. Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs. placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2020; 2020: GS3-01 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/1725
    PubMedGoogle Scholar
  • 12 Umanzor G, Cutler DL, Barrios FJ. et al. Oral paclitaxel with encequidar: The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: A phase III clinical study in metastatic breast cancer. Cancer Res 2020; 80 (Suppl. 04) GS6-01
    CrossrefPubMedGoogle Scholar
  • 13 Jang SH, Wientjes MG, Au JL. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 2001; 298: 1236-1242
    PubMedGoogle Scholar
  • 14 Umanzor G, Rugo HS, Barrios FJ. et al. Oral Paclitaxel and Encequidar (oPac+E) versus IV paclitaxel (IVPac) in the Treatment of Metastatic Breast Cancer (mBC) Patients (Study KX-ORAX-001): Progression Free Survival (PFS) and Overall Survival (OS) Updates. San Antonio Breast Cancer Symposium 2020; 2020 (04) PD1-08 https://www.abstractsonline.com/pp8/%23!/9223/presentation/716
    PubMedGoogle Scholar
  • 15 OʼShaughnessy J, Schwartzberg L, Piccart M. et al. Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane. San Antonio Breast Cancer Symposium 2020; 2020: GS4-01 Accessed March 16 2021. at: https://www.abstractsonline.com/pp8/%23!/9223/session/155
    PubMedGoogle Scholar
  • 16 businesswire. Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel. Accessed March 23, 2021 at: https://www.businesswire.com/news/home/20210322005211/en/Odonate-Therapeutics-Announces-Discontinuation-of-Development-of-Tesetaxel
    PubMedGoogle Scholar
  • 17 Yardley DA, Ismail-Khan RR, Melichar B. et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 2013; 31: 2128-2135
    CrossrefPubMedGoogle Scholar
  • 18 Dent R, Kim S-B, Oliveira M. et al. Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. San Antonio Breast Cancer Symposium 2020; 2020: GS3-04 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/672
    PubMedGoogle Scholar
  • 19 Kim SB, Dent R, Im SA. et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2017; 18: 1360-1372
    CrossrefPubMedGoogle Scholar
  • 20 Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800
    CrossrefPubMedGoogle Scholar
  • 21 Finn RS, Dering J, Conklin D. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11: R77
    CrossrefPubMedGoogle Scholar
  • 22 Hortobagyi GN. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med 2017; 376: 289
    CrossrefPubMedGoogle Scholar
  • 23 Slamon DJ, Neven P, Chia S. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol 2018; 36: 2465-2472
    CrossrefPubMedGoogle Scholar
  • 24 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
    CrossrefPubMedGoogle Scholar
  • 25 Tripathy D, Im SA, Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018; 19: 904-915
    CrossrefPubMedGoogle Scholar
  • 26 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
    CrossrefPubMedGoogle Scholar
  • 27 Prat A, Chaudhury A, Solovieff N. et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies. San Antonio Breast Cancer Symposium 2020; 2020: GS1-04 Accessed March 16 2021at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/665
    PubMedGoogle Scholar
  • 28 Modi S, Park H, Murthy RK. et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol 2020; 38: 1887-1896
    CrossrefPubMedGoogle Scholar
  • 29 Bardia A, Tolaney SM, Loirat D. et al. ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs. treatment of physicianʼs choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). Ann Oncol 2020; 31 (Suppl. 04) S1142-S1215 doi:10.1016/annonc/annonc325
    CrossrefPubMedGoogle Scholar
  • 30 Bardia A, Mayer IA, Vahdat LT. et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med 2019; 380: 741-751
    CrossrefPubMedGoogle Scholar
  • 31 Hurvitz SA, Tolaney SM, Punie K. et al. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2020; 2020: GS3-06 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/674
    PubMedGoogle Scholar
  • 32 Harbeck N, Johnston S, Fasching P. et al. High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE. San Antonio Breast Cancer Symposium 2020; 2020: PD2-01 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/781
    PubMedGoogle Scholar
  • 33 Braun S, Marth C. Circulating tumor cells in metastatic breast cancer – toward individualized treatment?. N Engl J Med 2004; 351: 824-826
    CrossrefPubMedGoogle Scholar
  • 34 Cristofanilli M, Budd GT, Ellis MJ. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791
    CrossrefPubMedGoogle Scholar
  • 35 Janni WJ, Yab TC, Hayes DF. et al. Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) – a global pooled analysis with individual patient data. San Antonio Breast Cancer Symposium 2020; 2020: GS4-08 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/685
    PubMedGoogle Scholar
  • 36 Gray RG, Rea D, Handley K. et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013; 31 (18 Suppl.): 5
    CrossrefPubMedGoogle Scholar
  • 37 Ma XJ, Salunga R, Dahiya S. et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008; 14: 2601-2608
    CrossrefPubMedGoogle Scholar
  • 38 Bartlett J, Sgroi D, Treuner K. et al. Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen – To offer more? (aTTom) trial. J Clin Oncol 2019; 37 (15 Suppl.): 505
    CrossrefPubMedGoogle Scholar
  • 39 Murthy RK, Loi S, Okines A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382: 597-609
    CrossrefPubMedGoogle Scholar
  • 40 Blondeaux E, Perachino M, Bruzzone M. et al. Chances of pregnancy after breast cancer, reproductive and disease outcomes: a systematic review and meta-analysis San Antonio Breast Cancer Symposium 2020; 2020: GS3-09 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/677
    PubMed